Colon Cancer, Rectal Cancer
Conditions
Keywords
DEXAMETHASONE, FLOXURIDINE, IRINOTECAN (CPT-11) CAMPTOSAR, OXALIPLATIN
Brief summary
The purpose of this study is to see how well patients tolerate the side effects of treatment with Floxuridine, Oxaliplatin and Irinotecan. We also want to know if these methods used together are a useful way of treating cancer. We have studied these drugs and know the best doses of each when they are used alone. We do not yet know how well the drugs work with each other. This study will tell us the best doses of each drug when they are given over the same period of time.
Interventions
DRUGFloxuridine, Oxaliplatin, CPT-11
For patients on the 4-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin (which is used to prevent blood from clotting) and saline. Whether the pump contains drug or heparin and saline, it will need to be emptied and refilled about every two weeks. We will inject either the drugs or the saline and heparin into the pump through the skin using a needle and syringe. In summary, 2 weeks of drug in the pump is followed by 2 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day as the pump is filled and emptied, ie. Day 1 and Day 15 of each cycle.
Sponsors
University of Medicine and Dentistry of New Jersey
Rutgers, The State University of New Jersey
Sanofi
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease. Confirmation of diagnosis must be performed at MSKCC. * Patient's liver metastases must be deemed unresectable and comprise \<70% of the liver parenchyma. * A patient may have had prior chemotherapy or be previously untreated. * Patient may not have received prior treatment with FUDR or \>2 doses of Oxaliplatin. * KPS \> or = to 60%. * WBC \> or = to 3,000 cells/mm3 and platelet count \> or = to 100,000 cells/mm3 within 14 days of registration. * Creatinine \< or = to 1.5 mg/dl within 14 days of registration. * Total serum bilirubin \< or = 2.0 mg/dl within 14 days of registration.
Exclusion criteria
* No active concurrent malignancies: except a patient's potentially resectable colorectal primary. * Patient must not have obstruction of GI or GU tract. * Patient must not have current, symptomatic peripheral sensory neuropathy. * No prior radiation to liver. * No active infection, ascites, or hepatic encephalopathy. * Age ≥ 18 years. * Female patients cannot be pregnant or lactating. * Signed informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine the MTD of hepatic arterial floxuridine (FUDR) & dexamethasone (Dex) given via implanted pump in combination w biweekly intravenous Oxaliplatin + systemic irinotecan (CPT-11) in patients w unresectable hepatic metastases from colorectal cancer. | conclusion of the study |
Secondary
| Measure | Time frame |
|---|---|
| To determine the preliminary anti-tumor activity of the aforementioned combination chemotherapy. | conclusion of the study |
| To procure normal and disease liver tissue for evaluation of TS, p53, p21, TOPO 1, DPD, and ERCC levels. | conclusion of the study |
Countries
United States
Outcome results
None listed